Profile: ChemoCentryx Inc (CCXI.O)
17 May 2019
ChemoCentryx, Inc., incorporated on November 8, 1996, is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of the Company's drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered. The Company's late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
The Company has a clinical development program for the treatment of patients with advanced pancreatic cancer with its drug candidate CCX872, its second inhibitor of CCR2. CCX872 is a potent and selective inhibitor of the human CCR2. The Company's drug candidate, vercirnon, is intended to control the inflammatory response underlying Inflammatory Bowel Disease (IBD) by targeting the chemokine receptor known as C-C chemokine receptor type 9 (CCR9). The Company's other early stage drug candidate is CCX507 is a second generation CCR9 inhibitor. CCX507 is selective for CCR9 relative to all other chemokine receptors, orally bioavailable.
850 Maude Ave
MOUNTAIN VIEW CA 94043-4022